View presentation

Update on
Penn Pharma
John Roberts,
Commercial Director
December 2012
The Business
Penn provides an integrated range of services to an international
client base.
 Pharmaceutical Development
 Manufacturing & Packing
 Support Services
Headquartered in South Wales since 1986, with 300+ staff (>95%
local) on 2 sites.
Trading for over 30 years, Penn is approved by MHRA (UK) and
Recognised for its export experience, Penn supplies EU, USA,
Japanese, Australia and South American markets (Queen’s Award
Winners 1993 and 2010)
£30m turnover with objective to double in next 4 years.
Core Services
Pharmaceutical Development
 Formulation Development
 Analytical Development
 Clinical Supplies
Manufacture & Packing
Solid Oral Dose
Oral Liquids
Clinical Trial Batches
High Containment
Controlled drugs
Support Services
 QP Services
 Storage & Distribution
 EU Portal Importation & Distribution
Penn & Welsh Government Support
Established in Penn, Bucks in 1979 and relocated to South
Wales in 1986 with WDA support.
Received consistent export marketing support from WDA, IBW,
and more recently WG (e.g. overseas visits, exhibitions, trade
Substantial support for training and development in technical
and management skills - Workforce Development Scheme, Skills
for Growth Scheme etc.
Most recently, WG provided a capital grant to help fund
important further expansion and job creation, as part of a £14m
total investment……….
Penn Contained Manufacturing Operations
A bespoke facility dedicated to the development and
manufacture of potent, oral solid dose products.
Potent compounds
Drugs with pharmacological activity at doses of 1mg or
Cytotoxic/cytostatic/immunosuppressive drugs
Teratogenic/embryotoxic drugs
Carcinogenic/mutagenic drugs
Certain hormones
Drugs with a known or estimated OEL of ≤10µg/m3 8h
Business Case for Investment
For many years Penn has successfully developed and
manufactured ‘potent’ products requiring the use of ‘contained
operations’ to protect both employees and customers.
The number of ‘potent’ compounds requiring oral solid dosage
form development and subsequent manufacture at the clinical and
commercial scale is increasing, esp. in oncology .
More than 1500 potent compounds in development by the
pharma industry.
Shortage of suitable state-of-the art facilities worldwide.
Increasing outsourcing of development and manufacturing, esp. of
potent compounds.
Consequently we have decided to invest in a new facility to
manufacture oral solid dosage forms within contained operations.
Project Milestones
Board Approval
Q3 2011
Building Design
Q3 2011
Planning Permission Granted
Q4 2011
Equipment URS defined
Q4 2011
Enabling works
Q1 2012
Final equipment choice
Q1 2012
Equipment Order
Q1 2012
Facility Construction Start
Q1 2012
Plant Installation Start
Q3 2012
Commissioning & Validation Start
Q4 2012
Facility / Equipment handover
Q1 2013
On Target
Thank you

similar documents